Latest Pharmaceutical Cannabis News

Cann Group Limited has successfully completed a significant debt restructure and equity raising, improving its financial footing and liquidity to support future growth.

Cann Group Limited has finalized a $15.3 million settlement with National Australia Bank, releasing all security and closing loan facilities as part of a broader debt restructuring. The company is advancing a $9 million new loan and a $9 million capital raise, including a share purchase plan closing November 17.

Cann Group Limited has extended the expiry of its NAB debt facilities by two weeks, providing a brief but vital window to advance its refinancing plans.

Althea Group Holdings reported $5.02 million in Q3 FY25 receipts, driven by strong growth at Peak Canada and the launch of Peak USA, while its pharmaceutical cannabis division faces steep revenue declines prompting strategic review.

Althea Group Holdings reported a 20% increase in customer receipts to $9.01 million for Q2 FY25, while addressing governance lapses and reviewing its FY25 guidance. The company is advancing operational improvements and cost savings as it prepares for a pivotal Federal Court hearing.

BOD Science has executed an asset sale deed transferring critical intellectual property rights to Optimus Salvus, marking a pivotal step in its Deed of Company Arrangement process.